Journal article
CX-5461 can destabilize replication forks in PARP inhibitor-resistant models of ovarian cancer
J Xuan, RB Pearson, E Sanij
Molecular and Cellular Oncology | TAYLOR & FRANCIS INC | Published : 2020
Abstract
Acquired drug resistance leads to poor clinical outcome in high grade serous ovarian cancer (HGSOC). We have demonstrated the efficacy of the novel drug CX-5461 in HGSOC is mediated through destabilization of DNA replication forks. The data highlights the potential of CX-5461 in overcoming a general mechanism of chemotherapeutic resistance.
Related Projects (2)
Grants
Awarded by Victorian Cancer Agency
Funding Acknowledgements
This work was supported by the National Health and Medical Research Council [1162052] and the Victorian Cancer Agency [MCRF19007].